Literature DB >> 19439955

Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist's point of view.

Heinz F Hammer1.   

Abstract

Laryngopharyngeal reflux of liquid and gaseous gastric contents should be considered in every patient with unexplained hoarseness. Pathophysiology and treatment of reflux-associated laryngitis are different from those of reflux esophagitis and therefore remain an unsolved puzzle. The laryngeal mucosa is considerably more sensitive to acid and pepsin than the mucosa of the esophagogastric junction. Therefore definitions of acid and nonacid reflux used for gastroesophageal reflux disease may not be helpful for explaining pathophysiologic mechanisms in the larynx or pharynx. A reflux symptom index and reflux finding score may be useful in helping to select the minority of patients who may benefit from acid-suppressive therapy; however, further research is needed. Further research is also needed to identify those patients who may require higher doses or prolonged duration of proton pump inhibitors or alternative treatments like prokinetics or alginate, or those patients who may benefit from surgical treatment of gastroesophageal reflux. Since symptoms of laryngopharyngeal reflux may predict esophageal adenocarcinoma, every patient with laryngopharyngeal reflux should have an upper gastrointestinal endoscopy, even if no classical symptoms of gastroesophageal reflux disease are present.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439955     DOI: 10.1159/000210098

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

1.  The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease.

Authors:  Byung-Joon Chun; Dong-Soo Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-05       Impact factor: 2.503

2.  Risk factors for laryngopharyngeal reflux.

Authors:  Murat Saruç; Elif Ayanoglu Aksoy; Eser Vardereli; Mehmet Karaaslan; Bahattin Ciçek; Umit Ince; Ferhan Oz; Nurdan Tözün
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-30       Impact factor: 2.503

3.  Double probe pH-monitoring findings in patients with benign lesions of the true vocal folds: comparison with typical GERD and the effect of smoking.

Authors:  Athanasios Beltsis; Panagiotis Katsinelos; Jannis Kountouras; Nikolaos Kamarianis; Christos Zavos; Agathoklis Pournaras; Dimitrios Kapetanos; Kostas Fasoulas; Chrysanthos Zamboulis; Nikolaos Eugenidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-25       Impact factor: 2.503

4.  The association between Helicobacter pylori and chronic otitis media with effusion.

Authors:  Ahmed Taha; Jacob Pitaro; Tsilia Lazarovitch; Limor Muallem-Kalmovich; Yael Garti; Haim Gavriel
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-30       Impact factor: 3.236

5.  High prevalence of reflux esophagitis among upper endoscopies in Chinese patients with chronic liver diseases.

Authors:  Bing Li; Bin Zhang; Jun Wei Ma; Peng Li; Lei Li; Yun Ming Song; Hui Guo Ding
Journal:  BMC Gastroenterol       Date:  2010-06-04       Impact factor: 3.067

Review 6.  Clinical significance of heterotopic gastric mucosal patch of the proximal esophagus.

Authors:  Vui Heng Chong
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

7.  Insulin Resistance is Associated with Chronic Laryngitis in Korean Women.

Authors:  J-H Cho; S-S Lee; K-D Han; Y-H Joo
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

8.  Pepsin Promotes Activation of Epidermal Growth Factor Receptor and Downstream Oncogenic Pathways, at Slightly Acidic and Neutral pH, in Exposed Hypopharyngeal Cells.

Authors:  Panagiotis G Doukas; Dimitra P Vageli; Clarence T Sasaki; Benjamin L Judson
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 9.  Pepsin and Laryngeal and Hypopharyngeal Carcinomas.

Authors:  Cheng-Yi Yin; Sha-Sha Zhang; Jiang-Tao Zhong; Shui-Hong Zhou
Journal:  Clin Exp Otorhinolaryngol       Date:  2020-07-24       Impact factor: 3.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.